Clinical Trial Update: Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 Infection [Phase 1, Phase 2]

View source ↗

Summary

Update on a completed Phase 1/2 clinical trial evaluating Bavituximab in combination with Ribavirin as initial treatment for chronic hepatitis C infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Bavituximab (bavituximab)
• Ribavirin (ribavirin)

Snippet

Sponsor: Peregrine Pharmaceuticals | Conditions: Hepatitis C | Phase 1, Phase 2 | Status: COMPLETED